Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARa and inhibits the growth of acute promyelocytic leukemia

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9875-9885

  Guo, Yongli ^a   Dolinko, Andrey V ^c   Chinyengetere, Fadzai ^a   Stanton, Bruce ^a   Bomberger, Jennifer M ^a   Demidenko, Eugene ^a,b   Zhou, Da Cheng ^d   Gallagher, Robert ^d   Ma, Tian ^a   Galimberti, Fabrizio ^a   Liu, Xi ^a   Sekula, David ^a   Freemantle, Sarah ^a   Dmitrovsky, Ethan ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1 LIKE UBIQUITIN ACTIVATING ENZYME; INTERFERON STIMULATED GENE 15 PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PROMYELOCYTIC LEUKEMIA PROTEIN; UBIQUITIN PROTEASE 43 PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN SPECIFIC PROTEASE 18 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPEPTIDASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRETINOIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649959433     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1100     Document Type: Article

References (43)

1. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-41.
2. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66:675-84.
3. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663-74.
4. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia 2003;17:1723-30. (Pubitemid 37185247)
5. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-15.
6. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
7. Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA 2002;99:3806-11.
8. Pitha-Rowe I, Hassel BA, Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 2004;279:18178-87.
9. Shah SJ, Blumen S, Pitha-Rowe I, Kitareewan S, Freemantle SJ, Feng Q, et al. UBE1L represses PML/RAR alpha by targeting the PML domain for ISG15ylation. Mol Cancer Ther 2008;7:905-14. (Pubitemid 351551044)
10. Finley D, Chau V. Ubiquitination. Annu Rev Cell Biol 1991;7:25-69.
11. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159-80.
12. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005;6:599-609. (Pubitemid 41081264)
13. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002;277:9976-81.
14. Baek KH. Conjugation and deconjugation of ubiquitin regulating the destiny of proteins. Exp Mol Med 2003;35:1-7. (Pubitemid 36336922)
15. Li XL, Blackford JA, Judge CS, Liu M, Xiao W, Kalvakolanu DV, et al. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 2000;275:8880-8.
16. Malakhova O, Malakhov M, Hetherington C, Zhang DE. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem 2002;277:14703-11.
17. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006;25:2358-67.
18. Rempel LA, Austin KJ, Ritchie KJ, Yan M, Shen M, Zhang DE, et al. UBP43 gene expression is required for normal Isg15 expression and fetal development. Reprod Biol Endocrinol 2007;5:13. (Pubitemid 46605669)
19. Ritchie KJ, Hahn CS, Kim KI, Yan M, Rosario D, Li L, et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 2004;10:1374-8. (Pubitemid 40022720)
20. Liu LQ, Ilaria R Jr, Kingsley PD, Iwama A, van Etten RA, Palis J, et al. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999;19:3029-38.
21. Zou W, Kim JH, Handidu A, Li X, Kim KI, Yan M, et al. Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. Biochem Biophys Res Commun 2007;356:193-9.
22. Martensen PM, Justesen J. Small ISGs coming forward. J Interferon Cytokine Res 2004;24:1-19.
23. Ritchie KJ, Zhang DE. ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 2004;15:237-46.
24. Nason-Burchenal K, Dmitrovsky E. The retinoids: cancer therapy and prevention mechanisms. In: Nau H, Blaner WS, editors. Handbook of experimental pharmacology, Vol. 139. Heidelberg: Springer-Verlag; 1999. p. 301-22.
25. Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 2007;99:41-52.
26. Nason-Burchenal K, Takle G, Pace U, Flynn S, Allopenna J, Martin P, et al. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 1998;17:1759-68.
27. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA 1999;96:14807-12. (Pubitemid 30019721)
28. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 1996;56:2945-8.
29. Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, et al. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 2004;10:2570-7.
30. Feng Q, Sekula D, Müller R, Freemantle SJ, Dmitrovsky E. Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene 2007;26:5098-106.
31. Bomberger JM, Barnaby RL, Stanton BA. The deubiquitinating enzyme USP10 regulates the post-endocytic sorting of cystic fibrosis transmembrane conductance regulator in airway epithelial cells. J Biol Chem 2009;284:18778-89.
32. Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, et al. G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 2008;33:397-404.
33. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 2008;7:3780-8.
34. Catic A, Fiebiger E, Korbel GA, Blom D, Galardy PJ, Ploegh HL. Screen for ISG15-crossreactive deubiquitinases. PLoS One 2007;2:e679.
35. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:2551-6.
36. Ding W, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998;92:1172-83.
37. Nason-Burchenal K, Allopenna J, Bègue A, Stéhelin D, Dmitrovsky E, Martin P. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998;92:1758-67. (Pubitemid 28406882)
38. Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol 2008;21:659-66.
39. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 1998;92:2244-51. (Pubitemid 28452964)
40. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de Thé H. PML nuclear bodies and apoptosis. Oncogene 2004;23:2819-24.
41. Reineke EL, Kao HY. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int J Biol Sci 2009;5:366-76.
42. Hofmann TG, Will H. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 2003;10:1290-9. (Pubitemid 37536734)
43. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-7.